04 August 2011

Stomach tumours genetically different

Stomach cancer tumours have genetic differences, which determine how they respond to treatment, researchers have found.


Stomach cancer tumours have genetic differences, which determine how they respond to treatment, researchers have found.

In identifying two distinct versions of the disease, scientists found that a certain regimen of chemotherapy is more effective on one tumour type, while another drug works best on the other. The study authors said their findings would help doctors more effectively treat gastric cancer patients.

"Our study is the first to show that a proposed molecular classification of gastric cancer can identify genomic subtypes that respond differently to therapies, which is crucial in efforts to customise treatments for patients," study senior author Dr Patrick Tan, associate professor in the Cancer and Stem Cell Biology Program at the Duke-National University of Singapore (NUS) Graduate Medical School, said.

A microscopic pathology test developed in the 1960s, known as the Lauren classification, is a general description (either intestinal or diffuse) of how well the tumour cells clump together. The Singapore-based team at the Duke-NUS Graduate Medical School, however, was able to distinguish gastric cancer tumours where the Lauren test could not.

"There is a general assumption in the field that intestinal and diffuse gastric cancers [as classified by Lauren] represent two very different versions of gastric cancer, and now genomic data confirms this by demonstrating that the two genomic subtypes have very different molecular patterns," said Tan.

In profiling 37 stomach cancer cell lines, the researchers found two distinct patterns. Moreover, in accurately defining these tumour subtypes, they were also able to observe differences in how well each responded to chemotherapy.

"The exact mechanistic reasons for this difference are currently unclear, and this is an area that we are actively working on," noted Tan, adding that the researchers are working to find more specific vulnerabilities to drugs.

The researchers said they plan further research in which gastric cancer tumours will be genetically profiled to determine the most effective treatment.

The study findings were published in the journal Gastroenterology.

More information

The American Cancer Society has more about stomach cancer.

(Copyright © 2010 HealthDay. All rights reserved.)


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules